• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

The cardiovascular effects of the continuous infusion of dobutamine in patients with severe cardiac failure.

作者信息

Leier C V, Webel J, Bush C A

出版信息

Circulation. 1977 Sep;56(3):468-72. doi: 10.1161/01.cir.56.3.468.

DOI:10.1161/01.cir.56.3.468
PMID:884803
Abstract

Twenty-five patients with left ventricular failure and low cardiac output received a 72 hour infusion of dobutamine (10-15 microgram/kg/min) in order to determine the cardiovascular properties of this new inotropic agent. Left ventricular contractile performance improved significantly during the infusion as measured by systolic time intervals and echocardiographic parameters. Mean PEP/LVET decreased from 0.76 +/- 0.03 to 0.58 +/- 0.03 (P less than 0.05). The percent change in internal dimension of the left ventricle from diastole to systole increased from 9.5 +/- 1 to 16.8 +/- 1 (P less than 0.05) and Vcf increased from 0.47 +/- 0.05 to 0.80 +/- 0.06 circ/sec (P less than 0.05). Mean cardiac output (nine patients) rose from 1.97 +/- 0.15 to 3.33 +/- 0.50 L/min/m2 while mean pulmonary capillary wedge pressure fell from 28 +/- 3 to 18 +/- 2 mm Hg during the infusion period (both P less than 0.05). These changes in cardiac function occurred without significant changes in heart rate, ventricular irritability, or blood pressure. Urine flow and urine sodium concentration increased during the infusion period. The improvement of cardiac function without the simultaneous development or exacerbation of undesirable effects (tachycardia, premature ventricular contractions, increased pulmonary or systemic resistance, tachyphylaxis, etc.) makes dobutamine a highly desirable inotropic agent.

摘要

相似文献

1
The cardiovascular effects of the continuous infusion of dobutamine in patients with severe cardiac failure.
Circulation. 1977 Sep;56(3):468-72. doi: 10.1161/01.cir.56.3.468.
2
Superiority of dobutamine over dopamine for augmentation of cardiac output in patients with chronic low output cardiac failure.多巴酚丁胺在增加慢性低心排血量心力衰竭患者心排血量方面优于多巴胺。
Circulation. 1977 Feb;55(2):375-8. doi: 10.1161/01.cir.55.2.375.
3
Comparative hemodynamic effects of inotropic and vasodilator drugs in severe heart failure.强心药和血管扩张药对重症心力衰竭患者血流动力学影响的比较
Circulation. 1977 Oct;56(4 Pt 1):528-33. doi: 10.1161/01.cir.56.4.528.
4
Comparative systemic and regional hemodynamic effects of dopamine and dobutamine in patients with cardiomyopathic heart failure.多巴胺与多巴酚丁胺对心肌病性心力衰竭患者的全身及局部血流动力学影响的比较
Circulation. 1978 Sep;58(3 Pt 1):466-75. doi: 10.1161/01.cir.58.3.466.
5
Comparative haemodynamic effects of dobutamine and isoproterenol in man.多巴酚丁胺和异丙肾上腺素对人体血流动力学影响的比较
Intensive Care Med. 1977 Aug;3(2):57-62. doi: 10.1007/BF01683062.
6
Cardiovascular effects of dobutamine in severe congestive heart failure.多巴酚丁胺对严重充血性心力衰竭的心血管效应。
Am Heart J. 1977 Aug;94(2):175-82. doi: 10.1016/s0002-8703(77)80277-9.
7
Efficacy of new inotropic drugs in clinical coronary heart failure.新型正性肌力药物在临床冠心病心力衰竭中的疗效
Am J Med. 1978 Jul;65(1):197-202. doi: 10.1016/0002-9343(78)90710-6.
8
Haemodynamic effects of dobutamine in patients with coronary artery disease.
J Int Med Res. 1977;5(1):10-7. doi: 10.1177/030006057700500102.
9
The relationship between plasma dobutamine concentrations and cardiovascular responses in cardiac failure.
Am J Med. 1979 Feb;66(2):238-42. doi: 10.1016/0002-9343(79)90537-0.
10
Milrinone and dobutamine in severe heart failure: differing hemodynamic effects and individual patient responsiveness.米力农和多巴酚丁胺用于严重心力衰竭:不同的血流动力学效应及个体患者反应性
Circulation. 1986 Mar;73(3 Pt 2):III175-83.

引用本文的文献

1
Fenoterol and dobutamine as SARS-CoV-2 main protease inhibitors: A virtual screening study.非诺特罗和多巴酚丁胺作为严重急性呼吸综合征冠状病毒2主要蛋白酶抑制剂:一项虚拟筛选研究。
J Mol Struct. 2021 Mar 15;1228:129449. doi: 10.1016/j.molstruc.2020.129449. Epub 2020 Oct 13.
2
Clinical Characteristics and Treatment of Cardiomyopathies in Children.儿童心肌病的临床特征与治疗
Curr Cardiol Rev. 2016;12(2):85-98. doi: 10.2174/1573403x12666160301115543.
3
Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Intensive care management of pulmonary hypertension.
沙特肺高血压诊断和治疗指南:肺高血压重症监护管理。
Ann Thorac Med. 2014 Jul;9(Suppl 1):S121-6. doi: 10.4103/1817-1737.134056.
4
Inotropes do not increase mortality in advanced heart failure.强心剂不会增加晚期心力衰竭患者的死亡率。
Int J Gen Med. 2014 May 20;7:237-51. doi: 10.2147/IJGM.S62549. eCollection 2014.
5
Acute Heart Failure Treatment.急性心力衰竭的治疗
Curr Emerg Hosp Med Rep. 2013 Jun 1;1(2). doi: 10.1007/s40138-013-0012-8.
6
Inotropic therapy for end-stage heart failure patients.终末期心力衰竭患者的正性肌力治疗
Curr Treat Options Cardiovasc Med. 2010 Oct;12(5):409-19. doi: 10.1007/s11936-010-0090-9.
7
The temporal hormesis of drug therapies.药物治疗的时间节奏效应。
Dose Response. 2006 May 1;3(3):414-24. doi: 10.2203/dose-response.003.03.009.
8
Intravenous vasodilator therapy in congestive heart failure.充血性心力衰竭的静脉血管扩张剂治疗
Drugs Aging. 2003;20(7):485-508. doi: 10.2165/00002512-200320070-00002.
9
Pharmacokinetic aspects of treating infections in the intensive care unit: focus on drug interactions.重症监护病房感染治疗的药代动力学方面:聚焦于药物相互作用。
Clin Pharmacokinet. 2001;40(11):833-68. doi: 10.2165/00003088-200140110-00004.
10
Dobutamine as bridge to angiotensin-converting enzyme inhibitor-nitrate therapy in endstage heart failure.多巴酚丁胺作为晚期心力衰竭患者过渡到血管紧张素转换酶抑制剂-硝酸盐治疗的桥梁。
Clin Cardiol. 2001 Mar;24(3):231-6. doi: 10.1002/clc.4960240311.